Brexit would irreparably damage UK pharma industry
![](/46/pdcnewsitem/04/12/88/nonstop%20recruitment.png)
A Brexit in the upcoming EU referendum could directly damage the UK pharmaceutical industry, according to NonStop Recruitment.
An analysis by the specialist pharmaceutical and life sciences recruitment consultancy found that the UK leaving the EU would mean the sector would still have to follow regulations to sell in the single market, but that it would have no say over what these regulations were. It would also mean the UK would lose out on the greater patent protection and support for research that it currently gains from being a member state, as well as the expertise of thousands of highly skilled professionals.
Matt Beedle, Team Leader within NonStop Pharma comments: “From our analysis and the many others that have been released it’s clear that the pharmaceutical and life sciences fields would be directly impacted in the case of a Brexit. Yes, the situation isn’t perfect at the moment however, the outlook would still be far worse if we were to vote leave. In this instance there’s a high chance that the EMA (European Medicines Agency) would relocate and therefore many of the pharma companies headquartered in the UK could leave – potentially to Ireland. This is because one of the major reasons many pharma firms have their headquarters in the UK is due to the proximity of the London-based EMA. In addition we’d still need to trade in the single market, however we would no longer have any say in what regulations we would be following, which would obviously damage our competitiveness and would likely weaken our position significantly. The sector would also struggle to keep hold of the thousands of European professionals who currently provide expertise to firms on these shores. We have such a powerful industry here that it seems like a huge error to leave, particularly at a time when our industrial output is growing at its fastest rate for four years, which has been heavily boosted by the pharma sector.”
“For NonStop as a business a leave vote would be particularly unwelcome. We place a big focus on providing the best possible working environment, part of which involves allowing our employees to work in any of our offices across Europe. A Brexit would mean we would face a much larger administrative burden to continue having a diverse workforce, something which we know directly contributes to our success as a business. And it’s not just us that would be affected, the knock on effects would impact all UK businesses that utilise the expertise of European professionals.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance